Improving SARS-CoV-2 variants monitoring in the absence of 1 genomic surveillance capabilities: a serological study in Bolivian 2 blood donors in October 2021 and June 2022 3

4

Lucia Inchauste¹, Elif Nurtop¹, Lissete Bautista Machicado², Yanine Leigue Roth³, 5 Shirley Lenz Gonzales⁴, Maria Luisa Herrera⁵, Katty Mina Villafan⁶, Pedro Mamani 6 7 Mamani⁷, Marcelo Ramos Espinoza⁸, Juan Carlos Pavel Suarez⁹, Juan Cansio Garcia Copa¹⁰, Yitzhak Leigue Zabala¹¹, Etzel Arancibia Cardozo¹², Pierre Gallian ^{1,13}, Xavier 8 de Lamballerie¹ and Stéphane Priet^{1*} 9

11 12	1	Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207), Marseille, France
13	2	Programa Nacional de Sangre, Ministerio de Salud y Deportes, La Paz, Bolivia
14	3	Banco de Sangre de Referencia Departmental de Beni, Beni, Bolivia
15	4	Banco de Sangre de Referencia Departmental de Chuquisaca, Sucre, Bolivia
16	5	Banco de Sangre de Referencia Departmental de Cochabamba, Cochabamba, Bolivia
17	6	Banco de Sangre de Referencia Departmental de El Alto, El Alto, Bolivia
18	7	Banco de Sangre de Referencia Departmental de La Paz, La Paz, Bolivia
19	8	Banco de Sangre de Referencia Departmental de Oruro, Oruro, Bolivia
20	9	Banco de Sangre de Referencia Departmental de Pando, Pando, Bolivia
21	10	Banco de Sangre de Referencia Departmental de Potosí, Potosí, Bolivia
22	11	Banco de Sangre de Referencia Departmental de Santa Cruz, Santa Cruz, Bolivia
23	12	Banco de Sangre de Referencia Departmental de Tarija, Tarija, Bolivia
24 25	13	Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
26		
27	*	Correspondence: <u>stephane.priet@univ-amu.fr</u> ; +33(0)4 13 73 21 51
28		
29	NOTE: T	his preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

Unlike genomic data, serological data have not been previously leveraged to evaluate the 31 SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were 32 lacking especially at the beginning of the pandemic. In 2021 and 2022 we estimated the 33 34 prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the feasibility of using virus serum neutralization data for variants thought to have circulated to 35 map their circulation across all departments over a year-long follow-up period. Anti-S1 and 36 anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-37 38 D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2. Between 2021 and 2022, the overall prevalence of anti-S1 and anti-NCP antibodies increased reaching values over 90%, 39 40 demonstrating that a large proportion of the Bolivian population was no longer naïve to the virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of 41 42 the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma continued to circulate in southernmost departments of the country and the emergence of 43 Omicron BA.1 was detected. These trends align with publicly available genomic data from 44 neighboring countries. Our serological analyses successfully identified both new antigenic 45 groups, such as Omicron BA.1, and individual variants related to previously circulating groups, 46 such as Delta. The study contributes insights into overall population immunity to SARS-CoV-47 2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes 48 the potency of seroprevalence studies in informing public health decisions and underscore their 49 value in capturing the initial phases of emerging epidemics when variant diversity is limited, 50 facilitating timely genomic surveillance setup. 51

52



56 Introduction

Low- and middle-income countries in the Latin American region are vulnerable to health crises due to a combination of factors such as poverty, fragile political and health systems, persistent and pervasive inequality in income, health care, and education, among others¹. The SARS-CoV-2 pandemic started in South America with the detection of the first case on February 26, 2020, at São Paulo, Brazil². Although it was initially thought that the pandemic would have less of an impact on this region due to its younger population structure, the pandemic eventually had a significant impact, accounting for 25% of infections worldwide³.

64 Seroprevalence studies are a valuable adjunct to active surveillance because they allow analysis of the level of immunity of a population to a specific pathogen without the need for prospective 65 testing, and also provide information on the frequency of cases that do not attract medical 66 attention⁴. During the first years of the SARS-CoV-2 pandemic, a few South American 67 population-based seroprevalence studies were conducted in Colombia, Perú, Chile, and Brazil⁵⁻ 68 ¹¹. Reported seroprevalence values varied through time and geographical location. Notably, 69 high prevalence was observed in locations such as Iquitos-Perú (70%) or Manaus-Brazil (54%) 70 after the first wave^{6,10}. However, an unexpected violent second wave occurred concomitantly 71 with the emergence of the Gamma variant, despite the high levels of seroprevalence reported 72 earlier¹⁰⁻¹². Despite the serious impact of COVID-19 on public health in Bolivia, research 73 studies are still lacking: one study reported a seroprevalence of 43.4% in January 2021 among 74 healthcare workers in the city of Cochabamba¹³, but no nationwide seroprevalence study is 75 currently available. 76

To date, the circulation of SARS-CoV-2 variants has mainly been studied through molecular 77 surveillance. However, in countries without significant genomic surveillance capabilities at the 78 79 start of the epidemic, it has become difficult to assess the spread and impact of variants. Here, we have attempted to reconstruct parts of the history of the spread of SARS-CoV-2 in Bolivia 80 by studying the prevalence and specific neutralizing capacity of anti-SARS-CoV-2 antibodies 81 in blood donors from all Bolivian departments after the second and third COVID-19 waves. 82 83 Based on the results obtained, we discuss the potential contribution of seroprevalence and seroneutralization studies of viral variants and their complementarity with viral genomics data 84 during the different phases of dissemination of a pathogen such as SARS-CoV-2. 85

86

88 Methods

89 Background

In Bolivia, the first case of SARS-CoV-2 was reported on March 10th, 2020, and to date 90 1 209 619 cases and 22 407 deaths have been reported¹⁴. As for the rest of South America, 91 Bolivia has experienced five waves of SARS-CoV-2 cases: the initial wave (May-September 92 2020), followed by a second (January-July 2021), a third (December 2021 to February 2022), 93 a fourth (June-August 2022) and the most recent (November 2022 to January 2023). Data on 94 variants circulating in each wave in South America is available in several free-access databases 95 (e.g., the PAHO dashboard) but Bolivian genomic data are scarce and only few sequences have 96 been deposited¹⁵⁻¹⁷. 97

During the first wave, COVID-19 cases in Bolivia neighboring countries were due to ancestral 98 and D614G SARS-CoV-2 strains (Supplementary Figure S1)¹⁵⁻¹⁷. During the second wave, 99 Alpha, Gamma, Lambda and Mu variants were the main types identified, with variable 100 101 distribution among countries. In contrast to Europe, the Alpha variant was not the most prevalent in any country of South America. Moreover, no specific wave was produced and no 102 103 associated increase in mortality was observed due to the circulation of the Delta variant. The start of the third wave, as in the rest of the world, was concomitant with the emergence and 104 105 spread of the Omicron (BA.1) variant. The next two waves were mainly caused by the Omicron 106 variants BA.2/BA.5 and BQ.1/XBB, respectively.

107

108 Specimens and ethical considerations

Samples were collected from volunteer blood donors that agreed to participate in the study and 109 provided written consent. The study was approved by the ethics committee of the Dr. Mario 110 Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N° FWA0002686) and by the National 111 Blood Program from the Ministry of Health and Sports of Bolivia. Sampling was conducted in 112 close collaboration with the National Blood Program and each Departmental Reference Blood 113 Bank. A first batch of 4238 serum samples was collected between August 26, and October 04, 114 2021. Samples were obtained from all Departmental Reference Blood Banks of Bolivia, which 115 included the cities of Beni (N=733), Chuquisaca (N=294), Cochabamba (N=500), La Paz 116 (N=500), El Alto(N=500), Oruro (N=500), Pando (N=414), Potosí (N=197), Santa Cruz 117 (N=600), Tarija (N=500). A second batch was collected between May 30 and June 23, 2022, 118

including a total of 1161 sera from the Departmental Reference Blood Banks of Cochabamba
(N=212), La Paz (N=264), Santa Cruz (N=186) and Tarija (N=499).

121

122 Vaccination coverage

Vaccination campaign against SARS-CoV-2 in Bolivia started on January 29, 2021¹⁸. 123 Following the SAGE recommendations, vaccination started for the healthcare workers, then 124 extended to the elderly, and people living with underlying health conditions and later expanded 125 to the general population. Vaccines distributed in Bolivia included the mRNA vaccines 126 127 Comirnaty (Pfizer-BioNTech) and mRNA-1273 (Moderna), the inactivated virus vaccines CoronaVac (Sinovac Biotech, China) and BBIBP-CorV (Sinopharm, China), the (adeno)viral 128 vector vaccines Ad26.CoV2.S (Johnson & Johnson), Vaxzevria (AstraZeneca), and Sputnik V 129 (Gamaleya Research Institute of Epidemiology and Microbiology). Administration of a booster 130 dose was started on October 11, 2021¹⁹. 131

SARS-CoV-2 vaccination coverage was estimated for both sampling periods (October 27, 2021 and May 30, 2022) based on data reported by the Bolivian Ministry of Health and the Bolivian National Institute of Statistics²⁰⁻²². To calculate vaccination coverage, the number of vaccine doses administered by the Bolivian Ministry of Health was related (by department and nationally) to the total eligible population according to the Bolivian National Institute of Statistics. At the time of the first and second sampling periods, the eligible population included individuals over 18 years of age and over 11 years of age, respectively.

139

140 Immunoassays

All serum samples were first screened using the commercial kit Anti-SARS-CoV-2 Quantivac ELISA IgG (Euroimmun) according to manufacturer's recommendations to detect anti-Spike S1 antibodies. Specimens with BAU/mL<25.6, $25.6 \le BAU/mL<35.2$, and BAU/mL ≥35.2 were considered negative, equivocal and positive, respectively.

145 Samples were also tested for the presence of anti-NCP SARS-CoV-2 IgG using an in-house

146 qSAT assay, as described elsewhere²³. Briefly, the CTD domain of the SARS-CoV-2 N protein

147 (EVAg, ref: 100P-03957) was coupled to a MAGPLEX® magnetic microsphere (Luminex

148 Corporation) using the xMAP® Antibody Coupling Kit (Luminex Corporation) following

149 manufacturer's recommendations (60 $pmol/10^6$ beads). The coupled beads were resuspended

and counted on a Countess™ II Automated Cell Counter (Thermo) to a final concentration of 150 $2x10^{6}$ beads/ml. Samples diluted in Wash Solution (Thermo) at 1/400 were incubated with 151 1,000 coupled beads per well for 1 h at room temperature in a plate shaker protected from light. 152 After two washes, the beads were incubated with R-Phycoerythrin AffiniPure F(ab')₂ Fragment 153 Goat Anti-Human IgG F(ab')₂ (Jackson ImmunoResearch) for 1 h at room temperature in a plate 154 shaker protected from light. After washing, antigen-antibody reactions were read on an 155 INTELLIFLEX® system (Luminex Corporation) and the results were expressed as median 156 fluorescence intensity (MFI). Cut-off values for each SARS-CoV-2 antigen for the S, RBD and 157 NCP were described elsewhere²³. 158

For virus Neutralization Tests (VNT), strains from the B.1 (Bav-Pat1/2020 strain [D614G]), 159 (SARS-CoV-160 P.1 (SARS-CoV-2/2021/JP/TY7-503 strain [Gamma]), B.1.617.2 2/2021/FR/0610 strain [Delta]), and B.1.1.529 (UVE/SARS-CoV-2/2021/FR/1514 strain 161 [Omicron BA.1]) lineages of SARS-CoV-2 were used. Except for Bav-Pat1/2020 strain 162 (courtesy of Prof. Drosten, Berlin), all strains were provided by the European Virus Archive 163 (EVAg) repository (www.european-virus-archive.com). VNTs were performed for samples 164 with a positive or equivocal result in the anti-Spike S1 ELISA as previously described²⁴. Four 165 separate VNT assays were performed in duplicate with strains representative of the D614G, 166 Gamma, Delta, and Omicron BA.1 variants. Briefly, the test consisted in mixing 110µL of a 167 serially diluted (from 1/20 to 1/40960) patient serum sample (in DMEM with 1% of 168 penicillin/streptomycin, Non-Essential Amino Acids and Glutamine), with 110µL of a fixed 169 quantity of a given SARS-CoV-2 strain, to reach a final concentration of 0.5 TCID₅₀/µL of 170 plasma dilution. This mixture was incubated for 1 hour at 37°C. One hundred µL was then 171 transferred onto a confluent Vero E6 TMPRSS2+ cells monolayer and incubated at 37°C under 172 173 5% of CO₂. On day 5 post infection, dilutions showing a cytopathic effect (CPE) were considered negative (no neutralization) and those without CPE were considered positive 174 (complete neutralization of the SARS-CoV2 inoculum). The neutralization titer referred to as 175 the highest serum dilution with a positive result. Specimens with a VNT titer ≥ 20 were 176 considered positive. 177

178

179 SARS-CoV-2 seroprevalence

Prevalence values for anti-S1 and anti-NCP antibodies, and for neutralizing antibodies (nAbs) against the ancestral D614G (D614G), Gamma (γ), Delta (δ), and Omicron BA.1 (o) variants

were calculated using the Prevalence package RStudio version R-4.0.3²⁵. Positive or negative status for each sample and every variable was determined using the cut-offs described above. For all variables, number of positive and negative results were used for prevalence computing. Regarding nAbs, prevalence values for each variant (D614G, γ , δ , o) in each department and

186nationwide were calculated using the regular seropositivity titer cut-off at 20 (samples with a187titer \geq 20 were considered positive) and an alternative "high level" seropositivity titer cut-off at

188 189 ≥640.

190 Evaluation of the circulating variants using a "VNT Titers ratio method"

The circulation of variants in Bolivia before October 2021 and June 2022 was first analyzed 191 through the distribution of samples exhibiting titers higher than the D614G ancestral strain for 192 193 a given variant of interest (γ , δ , o). The base 2 logarithm of VNT titer ratios (log2-ratios) for the following variants pairs was calculated: D614G/Gamma (D614G/ γ), D614G/Delta 194 195 (D614G/δ), D614G/Omicron BA.1 (D614G/o). Negative log2-ratio indicated that the variant in the denominator (γ, δ, o) had a higher titer than D614. A log2-ratio of 0 indicated that both 196 variants presented the same titer. To evaluate the circulation level of γ , δ , and σ variants under 197 increasingly stringent conditions, we calculated the proportion of the population with log2-ratio 198 values of ≤ 0 (variant titer equal to or greater than D614G), ≤ -1 (variant titer at least twice that 199 of D614G), and \leq -2 (variant titer at least four times that of D614G) for each department. 200

201

202 Quantification of the circulating variants according to antigenic groups

Antigenic mapping of SARS-CoV-2 based on the neutralizing activity of each variant²⁶⁻²⁸ enables us to group the ancestral variants D614G, Alpha, Delta, Lambda, and Epsilon in one group (GI), Beta, Gamma, Mu, Iota, and Zeta in a second group (GII), and Omicron and its derivatives into a third group (GIII). To initiate the quantification of the variants circulating in Bolivia, we initially employed a straightforward approach to estimate the percentage of samples in each antigenic group within each department of Bolivia using two different methods (the "Average titer method" and the "Variant assignment method").

210 Average titer method

To assess the neutralizing response across distinct antigenic groups, we used the average VNT 211 titer for the D614G and Delta variants to delineate antigenic group I (GI). Antigenic group II 212 (GII) was established based on the VNT titer for the Gamma variant, while antigenic group III 213 (GIII) was defined by the VNT titer for the Omicron BA.1 variant. For evaluating the 214 percentage of each antigenic group within different regions of Bolivia, GI was considered 215 dominant if its titer surpassed those of GII and GIII. Similarly, GII was considered if its titer 216 exceeded those of GI and GIII, and GIII was considered if its titer equaled or surpassed those 217 of GI and GII. Additionally, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and 218 219 Epsilon variants), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants), and the prevalences of GIII (from all Omicron-derived variants) were obtained for neighboring 220 221 countries of Bolivia using publicly accessible genomic data when available.

222 Variant assignment method

Assignment rules: We implemented several rules taking into account the previously described 223 decrease in neutralizing activity of variants²⁶⁻²⁸ to determine which of the four variants tested 224 was expected to be responsible for the main or last infection (Supplementary Figure S2). Main 225 rules relied on D614G/ γ , D614G/ δ , and D614G/ \circ log2-ratios to differentiate between D614G, 226 Gamma, Delta, and Omicron variants. Given that Tarija had the lowest variant circulation level 227 and the highest vaccination coverage among the departments analyzed as October 2021, this 228 department was chosen as a reference for establishing the D614G cut-off values for the 229 subsequent rules defining the infection by γ , δ and σ variants. Given that approximately 90% of 230 the population in this department exhibited D614G/ γ , D614G/ δ , and D614G/ \circ log2-ratios ≥ 0 , 231 ≥ 0 , and ≥ 1 respectively, the D614G variant was assigned to compliant samples. If any of these 232 log2-ratios fell below these threshold values, the corresponding variant (γ , δ , or σ) was assigned. 233 Secondary rules were applied on a fraction of samples when the log2-ratios for two pairs were 234 below the threshold values. Additional log2-ratios for Delta/Gamma (δ/γ), Gamma/Omicron 235 BA.1 (γ /o) and Delta/Omicron BA.1 (δ /o) pairs were thus considered to differentiate between 236 the two variants. If both the D614G/ γ and D614G/ δ log2-ratios were \leq -1, a δ/γ log2-ratio \leq 0 237 was chosen to indicate a Gamma infection, while a $\delta/\gamma \log 2$ -ratio ≥ 1 indicated a Delta infection. 238 When the D614G/o log2-ratio was ≤ 0 and the D614G/y log2-ratio was also ≤ -1 , a y/o log2-239 ratio ≥ 1 indicated a Gamma infection; otherwise (γ /o log2-ratio ≤ 0) Omicron BA.1 was 240 241 assigned. Similarly, if the D614G/o log2-ratio was ≤ 0 and the D614G/ δ log2-ratio was ≤ -1 , a δ /o log2-ratio \geq 1 suggested a Delta infection; otherwise (δ /o log2-ratio \leq 0) Omicron BA.1 was 242 assigned. 243

244 **Quantification according to assignment rules**: Variants assigned as D614G and Delta were 245 grouped in the antigenic group I, Gamma was set as the antigenic group II, and Omicron BA.1 246 as the antigenic group III. The percentage of samples in each antigenic group were calculated 247 for all departments for each sampling period.

248

249 Quantification of the circulating variants according to individual variants

250 The percentage of samples assigned through the Assignment Rules (cf. supra) to D614G,

251 Gamma, Delta or Omicron BA.1 was calculated for all departments for each sampling period.

253 **Results**

254 **Population studied**

A first sampling was carried out in blood donors from all Bolivian departments from August 26 to October 4, 2021, after the second epidemic wave (Supplementary Figure S1). A second sampling to follow the evolution of the virus 6 months later was carried out in the 3 most populated departments as well as in the most southern department (May 30 to June 23, 2022, corresponding to the phase before the fourth wave).

Among the 4738 blood donors included for the first period, age ranged from 18 to 64 years, with a median of 29 years (IQR, [23-37]). In the second period, 1161 blood donors were included, ranging in age from 18 to 82 years, with a median of 32 years (IQR, [25-41]). There was a balanced distribution of males (41.9% and 44.4%) and females (58.1% and 55.0%) for both periods.

265

266 Vaccination coverage

Vaccination coverage data obtained from the Bolivian Ministry of Health are summarized in
Supplementary Figure S3 for both periods with respect to vaccination coverage for the first
dose, 2 doses and a booster (3 doses).

In October 2021, the vaccination coverage of the Bolivian population with a first dose ranged from 47.6% (Potosí) to 70.3% (Tarija), reaching 59.3% at the national level. Coverage for the complete vaccination schedule (referred as two doses) varied from 38.4% (Pando) to 61.4% (Tarija), with a national average of 50.1%. The proportion of people who received one boost was very low, ranging from 0% (Pando) to 4.5% (Cochabamba), with a national average of 3.2%.

In May 2022, the coverage for one dose increased significantly, ranging from 62.3% (Pando)
to 84.3% (Tarija), with a national average of 76.5%. Full vaccination coverage (2 doses)
reached 46.6% (Pando) to 72.9% (Tarija), or 63.8% nationally. The one boost coverage reached
16.2% nationwide (10.9% (Beni) to 22.4% (Tarija)). Compared to the first sampling period,
regions with higher (Tarija) and lower (Pando) vaccine coverage remained the same.

281

282 Anti-SARS-CoV-2 Spike S1 and -NCP antibody prevalence

The anti-SARS-CoV-2 Spike S1 (anti-S1) antibody levels were assessed in each department for
both sampling periods (Figure 1A and 1C).

- In October 2021, at the national level, anti-S1 seroprevalence was 86.3% (95%CI: 85.3 87.6)
- and varied from 77.2% (Beni) to 92.4% (Potosí). Seroprevalence increased to 97.1% (95%CI:
- 287 95.9–97.9) by June 2022, ranging from 96.6% (Tarija) to 98.5% (La Paz).
- In October 2021, the anti-NCP seroprevalence was 60.8% (95%CI: 59.5 62.1) at a national level, increasing to 90.2% (95%CI: 88.3 – 91.7) in June 2022 (Figures 1B and 1D). In 2021, anti-NCP seroprevalence spanned from 52.7% (Pando) to 76.1% (Potosí). In 2022, the range extended from 85.5% (Santa Cruz) to 92.8% (Tarija). The anti-NCP antibody prevalence was always lower than anti-S1 antibody prevalence in October 2021 and June 2022. The anti-NCP increase in the 4 regions tested was around 30%, while the anti-S1 increase was 8-13%.
- 294

295 Prevalence of neutralizing antibodies.

296 Prevalence of nAbs against D614G

In October 2021, the nationwide prevalence of D614G nAbs at cut-offs \geq 20 and \geq 640 were 83.1% and 29.1% (Figure 2 and Supplementary Figure S4), respectively, with a geometric mean titer (GMT) of 159 (Supplementary Figure S5). The prevalence of D614G nAbs using the cutoff \geq 20 was consistently high across the entire country, ranging from 76.8% in Cochabamba to 90.3% in Potosí. Increasing the cut-off to \geq 640 revealed that Pando and Tarija had the highest (45.6%) and lowest (17.7%) prevalence, respectively. The rest of the country showed values ranging between 21.5% and 34.9%.

- By June 2022, D614G nAbs nationwide prevalence increased to 98.5% and 57.7% for the cutoff ≥ 20 and ≥ 640 respectively, with a GMT of 556. Prevalence obtained with the cut-off ≥ 20 was high across all tested departments, nearly reaching saturation. Using the cut-off ≥ 640 , the highest prevalence was observed in La Paz (73.2%) and the lowest in Tarija (42.9%).
- 308 *Prevalence of nAbs against Gamma*

In October 2021, the nationwide prevalence of Gamma nAbs at cut-offs \geq 20 and \geq 640 were 80.8% and 32.5% respectively, with a GMT of 208, showing a substantial circulation of Gamma, as expected. The 3 northern departments (Pando, La Paz and Beni) had the highest GMTs, varying between 310 and 352. The lowest and highest values were observed in Tarija

313 (63.7%) and Potosí (91.3%), respectively. Using the "high-level cut-off" (≥640), similar to
314 D614G, the highest prevalence was in Pando (48.1%), and the lowest in Tarija (13.0%).

By June 2022, the nationwide prevalence increased to 97.9% and 64.4% for the regular and

high-level cut-offs, respectively, with a GMT of 778. The prevalence for the regular cut-off was

above 96.5% across all tested departments. The highest and lowest prevalence values with the

high-level cut-off were observed in Cochabamba (68.5%), and La Paz (51.8%), respectively.

319 Prevalence of nAbs against Delta

In October 2021, despite expectations of low or no circulation of the Delta variant, we found 76.7% and 19.1% prevalence values at cut-offs \geq 20 and \geq 640 for Delta nAbs, respectively. This

reflects the high titers observed for D614G, as the result of cross-neutralization within antigenic

Group I. The Delta GMT was 81, compared to D614G (159) and Gamma (208).

By June 2022, the nationwide prevalence increased to 96.9% and 42.0% for the cut-offs ≥ 20

and ≥ 640 , respectively, with a GMT of 230. The prevalence obtained with the cut-off ≥ 20

exceeded 86.7% across all tested departments, and the highest and lowest prevalence values

with the cut-off ≥ 640 were found in La Paz (43.9%) and Santa Cruz (34.1%), respectively

328 Prevalence of nAbs against Omicron BA.1

In October 2021, prevalence for Omicron BA.1 was low (37.9% and 2.1% for the cut-off \geq 20 and \geq 640, respectively), with a GMT of 23. In the absence of Omicron BA.1 circulation at this time, this prevalence reflects cross-neutralization with D614G and Gamma.

By June 2022, nationwide prevalence increased to 90.7% and 19.9% for the cut-offs \geq 20 and \geq 640, respectively, with a GMT of 127. The highest prevalence at the cut-off \geq 640 was recorded

- in Tarija (21.1%), and the lowest in Santa Cruz (13.0%).
- 335

336 Evaluation of the circulating variants

This was performed using the "VNT Titers ratio method" (see Methods for details). Increasingly stringent conditions (percentage of individuals in the population with titers of variants equivalent to, twice or four times that of D614G) were tested (Figure 3 and Supplementary Figure S6).

341 *Circulation of Gamma*

342 In October 2021, in the northern part of Bolivia, encompassing the Pando, La Paz, Beni, and

343 Cochabamba departments, the population exhibited the highest percentage of individuals with

- Gamma titers superior to D614G. Conversely, Tarija (South) showed the lowest percentage.
- 345 This trend remained consistent across all conditions, including the most stringent ones.
- By June 2022, the Gamma variant was more actively circulating in Tarija, Cochabamba, and
 Santa Cruz. Compared to the first sampling period, this variant was less active in La Paz.

348 We conclude that the gamma variant circulated mainly in the north of Bolivia before

- 349 October 2021, then spread to the southern regions of the country.
- 350 Circulation of Delta and Omicron BA.1
- In October 2021, evidence for the circulation of the Delta and Omicron BA.1 variants was
 minimal, as expected (Supplementary Figure S1)¹⁵⁻¹⁷.
- 353 By June 2022, in contrast, the departments tested displayed an increase in the percentage of the
- population with Delta and Omicron BA.1 titers superior to D614G. The highest values for both
- 355 Delta and Omicron BA.1 were found in Tarija and Cochabamba, and the lowest in La Paz and356 Santa Cruz.
- 357 We conclude that there is serological evidence for the circulation of both Delta and 358 Omicron BA.1 variants after October 2021.
- 359

360 Quantification of the circulating antigenic groups

Using two approaches (the "Average titer method" and the "Variant assignment method"), the circulating antigenic groups were quantified (Figure 4 and Supplementary Figure S7). The nAbs responses resulting mainly from vaccination, ancestral, and Delta variants were clustered in group I (GI), and Gamma and Omicron BA.1 were the representatives of groups II (GII) and III (GIII), respectively. These two approaches yielded highly congruent results that were also in agreement with the abovementioned results (Figure 3). Data from the "Average titer method" was exposed in the following section (Figure 4).

368 Antigenic Group I

In October 2021, the percentages of GI-associated nAbs (GI-nAbs) spanned from 25.1%
(Cochabamba) to 80.9% (Tarija). The southernmost departments (Oruro, Potosí, and Tarija)

- 371 exhibited the highest values, aligning with genomic prevalence from surrounding countries for
- which GI variants circulated more in Argentina (74.4%), Chile (57.4%) and Perú (79.4%).
- **By June 2022**, the percentages of GI-nAbs extended from 30.2% (Tarija) to 79.3% (La Paz).
- 374 Compared to October 2021, the departments of La Paz and Cochabamba showed an increase in
- the levels, while Santa Cruz and Tarija exhibited a decrease.

376 Antigenic Group II

In October 2021, the percentages of GII-associated nAbs (GII-nAbs) spanned from 19.1%
(Tarija) to 74.9% (Cochabamba). The northern departments (Pando, La Paz, Beni, and
Cochabamba) presented the highest levels, which reflects the circulation in neighboring Brazil
(80.5%).

By June 2022, the percentages of GII-associated nAbs (GII-nAbs) spanned from 16.5% (La Paz) to 62.8% (Cochabamba). The southern departments of Santa Cruz and Tarija showed an increase, while the northern departments of La Paz and Cochabamba showed a decrease in this response.

385 Antigenic Group III

In October 2021, no evidence of circulation of GIII variants was observed from GIII-associated
 nAbs (GIII-nAbs) in Bolivia, or genomic surveillance derived data from surrounding countries.

By June 2022, the percentages of GIII-nAbs varied from 1.7% (Santa Cruz) to 8.9% (Tarija).
GIII-nAbs increased across all tested departments, *i.e.* the method was capable of detecting the
emergence of the new antigenic group.

We conclude that these serological data nicely align with the circulation of each antigenic
group in the neighboring countries as computed from accessible genomic surveillance data,
particularly at the first sampling period (Figure 4 and Supplementary Figure S1).

394

395 Quantification of the individual variant circulation

The prevalence of individual variants, assigned through the Assignment Rules was examined across all departments, showing similar trends with the above methods but offering a more accurate assessment of ancestral and Delta variant circulation and possible insights into the

weight of vaccination in the generation of ancestral D614G-induced nAbs antibodies (FigureS6 and S7).

401 *Quantification of ancestral D614G related variants circulation*

402 In October 2021, Tarija exhibited the highest D614G prevalence, while the northern 403 departments had some of the lowest circulation rates, a pattern consistent with vaccination 404 coverage data (Supplementary Figure S3) and the results observed above.

- **By June 2022,** the southernmost departments of Santa Cruz, and Tarija, saw a reduction in D614G prevalence. This trend comes with a higher level of Gamma circulation observed in these two departments (see above), further supporting the hypothesis of ongoing Gamma circulation between 2021 and 2022. In the department of Cochabamba, no significant change in D614G prevalence was observed (28.3% in October 2020 to 26.6% in June 2022). In contrast, La Paz experienced a notable surge (+40%) in D614G prevalence, consistently with the antigenic group analysis.
- 412 *Quantification of Delta circulation*

In October 2021, a low circulation of Delta was observed in all departments, ranging from 1.1% (Pando) to 9.1%(Tarija). As a result, the method was able to detect the appearance of the Delta variant, despite its belonging to the same antigenic group as other variants circulating previously.

417 **By June 2022,** the prevalence of Delta remained stable or decrease across the tested 418 departments, with prevalences ranging between 1.5% (La Paz) and 9.1% (Tarija).

419

421 Discussion

To our knowledge, we are reporting the first serological study of SARS-CoV-2 to be carried out in Bolivia in 2021 and 2022, which included blood donors from all the country's departments. This study enabled us to estimate the level of immunity of the population to SARS-CoV-2 nationwide and in the different regions of the country, thus providing valuable information on the circulation of these variants in Bolivia.

427 Our study has limitations. Firstly, the study was limited to blood donors in the major cities of 428 Bolivia and may therefore not be fully representative of the populations of the country as a 429 whole. In addition, our results are based on serological data and may not be strictly identical to 430 the genomic data from a quantitative point of view, although they are likely to reflect similar 431 trends and distributions (see below).

432 Epidemiological assessment

As of October 2021, our data showed an anti-S1 SARS-CoV-2 seroprevalence of 86.3%, 433 434 indicating that a large part of the population had immunity against SARS-CoV-2 following infection, vaccination, or both (Figure 1). Comparing the vaccination coverage with the anti-S1 435 antibody prevalence, we can infer that significant viral transmission occurred in the population 436 before October 2021 (Figure 1 and Supplementary Figure S3). These epidemiological data are 437 in agreement with other population-based studies performed on the first half of 2021 in Perú 438 and in the northwest of Brazil that reported high SARS-CoV-2 prevalence (63.6% and 65.0%, 439 respectively)^{6,10}. In Bolivia, the prevalence observed a few months later was even higher, 440 suggesting sustained virus circulation. By June 2022, although our sample was limited to four 441 departments, the data show a clear trend towards saturation in the prevalence of anti-S1, 442 suggesting that almost the entire population had been vaccinated and/or infected by that time. 443 With vaccination coverage having increased by around 13% (both for those who had received 444 two doses and those who had received the booster), the significant increase (+31.2%) in the 445 seroprevalence of anti-NCP antibodies indicates that a large proportion of the population has 446 447 been exposed to the virus between October 2021 and June 2022 (Figure 1). Even if a proportion of newly vaccinated individuals had received an inactivated vaccine likely to generate an anti-448 NCP response, this cannot explain the observed increase in the prevalence of anti-NCP 449 antibodies²⁹⁻³¹. This corresponds to the emergence of the Omicron BA.1 variant, which has 450 been shown to cause a high rate of infection worldwide^{32,33}. 451

452 Consistently, as of October 2021, the prevalence of nAbs against the ancestral D614G (83.1%) 453 and Gamma (80.8%) variants was very high throughout the country (Figure 2 and 454 Supplementary Figure S4). The 3 northern departments (Pando, La Paz and Beni) were the most 455 exposed to the Gamma variant, as reflected by the highest Gamma GMTs (Supplementary 456 Figure S5). By June 2022, the prevalence of neutralizing antibodies against all variants had 457 increased, reaching values higher than 90%, demonstrating that a large proportion of the 458 Bolivian population was no longer naïve to the virus.

When looking at nAbs with high neutralization titers, new variant circulation patterns emerged (Figure 2 and Supplementary Figure S4). Some departments in the northern part of Bolivia, especially Pando, may have suffered a greater impact during the two first waves, since nAbs titers were higher for both the D614G and Gamma variants as of October 2021. To gain further insight into the variant circulation, we proposed additional analyses ("VNT Titers ratio method", "Average titer method", "Variant assignment method"; Figures 3 and 4 and Supplementary Figures S6 to S8).

As of October 2021, a higher circulation of GII/Gamma was confirmed in northern Bolivia. 466 Moreover, it is likely that the first two waves had a significant impact on Pando, since (despite 467 having the lowest vaccine coverage in the country) high percentages of nAbs responses to the 468 ancestral D614G and Gamma variants were observed. On the other hand, the southernmost 469 department (Tarija) was probably the least affected, as it had the highest percentage of 470 neutralizing response to ancestral viruses and the lowest to Gamma, which is consistent with 471 its high vaccination coverage (the highest in the country). As for Delta, limited circulation was 472 473 observed across the country, corresponding to the beginning of its circulation in Latin America (Supplementary Figure S1). As expected, no evidence of Omicron BA.1 was observed. 474

By June 2022, analyses showed that GII/Gamma continued to circulate in southernmost 475 departments (Cochabamba, Santa Cruz, and Tarija). Besides, the high level of nAbs against 476 GII/Gamma, observed in the first sampling period, in the population of La Paz seems to have 477 waned and in the contrary GI/D614G nAbs have risen (+40%). This observation cannot be 478 479 explained solely by an increase in vaccination coverage (Supplementary Figure S3), since vaccination increased by only 13%. GI/D614G nAbs augmentation could be related to the 480 circulation of another GI variant, such as Lambda (which has circulated in the neighboring 481 country of Perú), or alternatively, the infection by the Delta and/or Omicron BA.1 variant may 482 have boosted the level of pre-existing anti-D614G nAbs in the population³⁴⁻³⁷. This boost of 483

pre-existing Abs phenomenon, known as antigenic sin, has been extensively documented in the 484 context of influenza infections and vaccinations^{38,39}. As for Delta, prevalences did not change 485 significantly, between October 2021 and June 2022, reflecting the limited Delta wave in Latin 486 America compared to Europe⁴⁰. Despite a significant global wave of the Omicron BA.1 variant 487 in South America, less than 9% of the Bolivian population tested displayed a neutralizing 488 antibody response against Omicron BA.1. This lower-than-expected nAbs response could be 489 attributed to the possibility that this variant increased the levels of pre-existing nAbs to previous 490 variants³⁴⁻³⁷. 491

492 Significance of serological results

To assess the significance and robustness of our serological results, we compared the results obtained with the different methods used and with genomic data from neighboring countries. We found that the patterns of circulation of antigenic groups/variants were consistent across the different serological methods used (Figure 4 and Supplementary Figures S7 and S8) and that they nicely aligned with the percentage of each antigenic group/variants in the neighboring countries as computed from accessible genomic surveillance data (Supplementary Figure S1).

499 Serological analyses allowed detecting the emergence of a new antigenic group (e.g., Omicron BA.1), but also of an individual variant related to a previously circulating antigenic group (e.g., 500 501 Delta). Overall, the accuracy of the mapping seems to have diminished with time, the number of variants that have been circulated, vaccination and the saturation of prevalence estimates. As 502 an example, the prevalence values found for Omicron BA.1 in June 2022 are likely to be 503 underestimated (see Figure 4 and Supplementary Figures S1 and S8). Although the detection 504 of a new antigenic group remained possible in this specific study during the late period of 505 variants circulation, our results argue in favor of the greater usefulness of seroepidemiological 506 studies for documenting the early stages of a new epidemic. This is of great interest because it 507 gives time to set up genomic surveillance in countries with limited sequencing capacity at the 508 start of an epidemic emergence. 509

510

In conclusion, our study represents the first large-scale survey conducted in all the departments of Bolivia, with a follow-up period of almost a year. This has enabled us to document ongoing viral circulation and better characterize the epidemiology of SARS-CoV-2 in Latin America, as well as providing essential information on the successive waves that have occurred in Bolivia. In particular, despite a high prevalence in 2022, which could suggest the development

of herd immunity, subsequent waves demonstrate the virus ability to adapt and continue circulating in a population that is no longer naïve. Our results confirm and reiterate that seroprevalence studies are a powerful tool for informing public health decision-making. Our findings strongly support the idea that seroepidemiological studies are valuable for capturing the initial phases of a new epidemic, giving time for the establishment of genomic surveillance in countries with limited sequencing capacity at the onset of an emerging epidemic.

522

523 Conflict of Interest

524 All the authors declare no competing interests.

525 Funding Source

This study was supported by the French National Research Institute for Sustainable Development (IRD), the project EMERGEN-PRI #22275 of the ANRS I MIE (INSERM), and the European Union's Horizon 2020 research and innovation program (European Virus Archive Global, grant agreement No. 871029). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

531 Ethical Approval

Samples were collected randomly from volunteer blood donors that agreed to participate in the study. Written consent was obtained from all blood donors. The study was approved by the ethics committee of the Dr. Mario Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N° FWA0002686) and by the National Blood Program from the Ministry of Health and Sports of Bolivia. Sampling was carefully conducted in close collaboration with the National Blood Program and each Departmental Reference Blood Bank.

538 Authors Contributions

LI, XdL, and SP conceived the study design. LBM, LI, RFZ, SLG, MLH, MLP, VT, RVFF, JCPS, PAO, YLZ, and EAC coordinated and managed sampling. LI and EN performed the serological assays. LI and SP performed the data curation. LI, XdL, and SP prepared the draft of the manuscript. All the authors have reviewed, contributed and approved the final manuscript.

544 Acknowledgments

545 The authors thank all professionals from the Departmental Reference Blood Banks. A special

- thanks to Dra. Daniela Azurduy, Dra. Vanessa Telleria, Dra. Cecilia Peralta, Dra. Rosario 546
- Quintanilla, Dra. Rosa Escalier, Dra. Patricia Achacollo Olmo, Dra. Raquel Verónica Figueredo 547

Flores, Dr.Ronald Flores Zabala, and Dra. Maria Luisa Patón for their support and management 548

to carry out the sampling for the project. We would also like to thank the collaboration of the 549

- Ministerio de Salud y Deportes, the Viceministerio de Gestión del Sistema de Salud and the 550
- Dirección de Redes de Servicios de Salud. 551
- 552

References 553

554 1. The L. COVID-19 in Latin America: a humanitarian crisis. The Lancet 2020; 396(10261): 1463.

555 2. Melo CML, Silva GAS, Melo ARS, Freitas AC. COVID-19 pandemic outbreak: the Brazilian reality 556 from the first case to the collapse of health services. Anais da Academia Brasileira de Ciencias 2020; 557 92(4): e20200709.

558 The L. COVID-19 in Latin America-emergency and opportunity. *Lancet (London, England)* 2021; 3. 559 **398**(10295): 93.

560 Wu KM, Riley S. Simulation-guided design of serological surveys of the cumulative incidence of 4. 561 influenza infection. BMC infectious diseases 2014; 14: 505.

562 Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, et al. SARS-CoV-2 prevalence associated to low 5. 563 socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. EClinicalMedicine 2021; 34: 100801. 564

- 565 Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 6. 566 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. The Lancet Global 567 *Health* 2021; **9**(7): e925-e31.
- 568 7. Vial P, González C, Icaza G, et al. Seroprevalence, spatial distribution, and social determinants 569 of SARS-CoV-2 in three urban centers of Chile. BMC infectious diseases 2022; 22(1): 99.
- 570 Mercado-Reyes M, Malagón-Rojas J, Rodríguez-Barraquer I, et al. Seroprevalence of anti-SARS-8. 571 CoV-2 antibodies in Colombia, 2020: A population-based study. The Lancet Regional Health – Americas 572 2022; 9.
- 573 9. Nicolete VC, Rodrigues PT, Fernandes ARJ, et al. Epidemiology of COVID-19 after Emergence of 574 SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021. Emerging infectious diseases 2022; 28(3): 575 709-12.

576 10. Buss LF, Prete CA, Jr., Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the 577 Brazilian Amazon during a largely unmitigated epidemic. Science (New York, NY) 2021; 371(6526): 288-578 92.

579 Prete CA, Buss LF, Buccheri R, et al. Reinfection by the SARS-CoV-2 Gamma variant in blood 11. 580 donors in Manaus, Brazil. BMC infectious diseases 2022; 22(1): 127.

581 Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite 12. 582 high seroprevalence. The Lancet 2021; 397(10273): 452-5.

583 13. Saba Villarroel PM, Castro Soto MdR, Undurraga V, et al. High SARS-CoV-2 Prevalence among 584 Healthcare Workers in Cochabamba, Bolivia. Viruses 2022; 14(2): 232.

585 14. WHO. WHO Coronavirus (COVID-19) Dashboard. 2023. https://covid19.who.int/ (accessed 586 13/11/2023.

SARS-CoV-2 Variants Tracking in the Region of the Americas. 587 15. PAHO. 2023. 588 https://ais.paho.org/phip/viz/SARS_CoV2_variants_regional.asp (accessed 13/04/2023.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.23.23298957; this version posted November 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

16. 589 GISAID. Phylodynamics of pandemic coronavirus in Latin America and the Caribbean. 590 11/04/2023 2023. 591 https://phylodynamics.pandemicprepardness.org/dist/start.html?id=TGF0aW4IMjBBbWVyaWNh&s= 592 1&h=0 (accessed 13/04/2023. 593 Hodcroft E. CoVariants. 12/04/2023 2023. https://covariants.org/ (accessed 13/04/2023. 17. 594 18. Bolivia MdSyDd. Inicia El Proceso de Vacunación Al Personal de Salud Que Lucha en Primera 595 Línea Contra la Pandemia. 2021. https://www.minsalud.gob.bo/5230-inicia-proceso-vacunacion 596 (accessed 17/04/2023. 597 Bolivia MdSyDd. Salud Dispone 800.000 Vacunas Para Inmunizar Con Dosis Adicional A 19. 598 Mayores De 60 Años Y Con Patologías De Base. 2021. https://www.minsalud.gob.bo/6104-salud-599 dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-600 patologias-de-base (accessed 02/05/2023. 601 Bolivia MdSyDd. Reporte de Vacunacion Contra la COVID-19 al 30 de Mayo de 2022. 2022. 20. 602 https://www.minsalud.gob.bo/6729-covid-19-salud-informa-que-esta-jornada-se-aplicaron-10-393-603 dosis-en-el-pais-y-casos-positivos-llegan-a-203 (accessed 02/05/2023. 604 21. Bolivia MdSyDd. Reporte de vacunacion contra la COVID-19 al 27 de octubre 2021. 2021. 605 https://www.minsalud.gob.bo/6163-covid-19-hasta-hoy-la-inmunizacion-alcanza-a-7-650-594-606 vacunas-aplicadas-con-primeras-segundas-unidosis-y-tercera-dosis (accessed 02/05/2023. 607 22. INE. Población Y Hechos Vitales; Proyecciones de Población, Revisión 2020. 2023. 608 https://www.ine.gob.bo/index.php/censos-y-proyecciones-de-poblacion-sociales/ (accessed 609 02/05/2023. 610 23. Inchauste L, Nurtop E, Brisbarre N, Gallian P, de Lamballerie X, Priet S. Exploring cell-free assays 611 for COVID-19 serosurvey. Submitted 2023. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of 612 24. antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral research 2020; 181: 613 614 104880. 615 25. Devleesschauwer B, Torgerson P, Charlier J, et al. Package 'prevalence'. 2013. 616 26. Mykytyn AZ, Rissmann M, Kok A, et al. Antigenic cartography of SARS-CoV-2 reveals that 617 Omicron BA.1 and BA.2 are antigenically distinct. Sci Immunol 2022; 7(75): eabq4450. 618 Wilks SH, Muhlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and 27. 619 serological responses. Science (New York, NY) 2023; 382(6666): eadj0070. 620 28. van der Straten K, Guerra D, van Gils MJ, et al. Antigenic cartography using sera from sequence-621 confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. 622 Immunity 2022; 55(9): 1725-31 e4. 623 29. Muena NA, García-Salum T, Pardo-Roa C, et al. Induction of SARS-CoV-2 neutralizing antibodies 624 by CoronaVac and BNT162b2 vaccines in naï ve and previously infected individuals. eBioMedicine 625 2022; 78. 626 30. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. 627 Science (New York, NY) 2020; 369(6499): 77-81. 628 Dashdorj NJ, Wirz OF, Roltgen K, et al. Direct comparison of antibody responses to four SARS-31. 629 CoV-2 vaccines in Mongolia. Cell Host Microbe 2021; 29(12): 1738-43 e4. 630 32. Silva SJRd, Kohl A, Pena L, Pardee K. Recent insights into SARS-CoV-2 omicron variant. 2023; 631 **33**(1): e2373. 632 33. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. 633 Lancet (London, England) 2021; 398(10317): 2126-8. 634 34. Quandt J, Muik A, Salisch N, et al. Omicron BA.1 breakthrough infection drives cross-variant 635 neutralization and memory B cell formation against conserved epitopes. Sci Immunol 2022; 7(75): 636 eabq2427. 637 35. Kaku CI, Bergeron AJ, Ahlm C, et al. Recall of preexisting cross-reactive B cell memory after 638 Omicron BA.1 breakthrough infection. *Sci Immunol* 2022; **7**(73): eabq3511. 639 36. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing 640 antibodies elicited by SARS-CoV-2 infection. Science (New York, NY) 2021; 372(6549): 1413-8.

- 641 37. Gallian P, Brisbarre N, Nurtop E, et al. Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1. Vox Sang 2023; 118(5): 642
- 407-8. 643
- Viboud C, Epstein SL. First flu is forever. Science (New York, NY) 2016; 354(6313): 706-7. 644 38.

645 39. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin: Separating Good From Evil. J Infect Dis 2017; 215(12): 1782-8. 646

- 647 40. Giovanetti M, Fonseca V, Wilkinson E, et al. Replacement of the Gamma by the Delta variant
- in Brazil: Impact of lineage displacement on the ongoing pandemic. Virus Evol 2022; 8(1): veac024. 648



Figure 1: Prevalence of anti-SARS-CoV-2 Spike S1 and -NCP antibodies in Bolivia as October 2021 and June 2022.

The prevalence of anti-SARS-CoV-2 Spike S1 (A, C) and -NCP (B, D) antibodies was reported for each department in Bolivia and nationwide as October 2021 (A, B) and June 2022 (C, D).



Figure 2: Prevalence of neutralizing anti-SARS-CoV-2 antibodies in Bolivia as October 2021 and June 2022. The prevalence of neutralizing antibodies was reported for each department in Bolivia and nationwide for the D614G (A, E), Gamma (B, F), Delta (C, G) and Omicron BA.1 (D, H) variants as October 2021 (upper panel: A, B, C, D) and June 2022 (lower panel: E, F, G, H). The prevalence was obtained with the positivity cut-off \geq 640.



Figure 3: Variant circulation in Bolivia as October 2021 and June 2022.

Percentage of the population exhibiting titers for Gamma, Delta, and Omicron BA.1 being at least equivalent to (log2-ratios ≤ 0 , upper panel: A, B, C, D), twice (log2-ratios ≤ -1 , middle panel: E, F, G, H), or four times (log2-ratios ≤ -2 , lower panel: I, J, K, L) that of D614G are presented for each department of Bolivia. Results for D614G/ γ are depicted in blue as October 2021 (A, E, I) and June 2022 (B, F, J). Results obtained as June 2022 for D614G/ δ and for D614G/ σ are depicted in green (C, G, K) and in red (D, H, L), respectively. D614G: ancestral D614G variant; γ : Gamma variant; δ : Delta variant; o: Omicron BA.1 variant.



Figure 4: Quantification of SARS-CoV-2 circulating antigenic groups in Bolivia by Average titer method as October 2021 and as June 2022.

Percentage of the population in each department presenting a neutralizing antibody response against a defined antigenic group, including the GI (green), GII (blue), GIII (red), using the Average titer method.

For antigenic group assignment by VNT, D614G and Delta variants were cluster in to the antigenic group I (GI), antigenic group II (GII) corresponded to the Gamma variant, while antigenic group III (GIII) was defined by the Omicron BA.1 variant (see methods for details). For evaluating genomic data, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and Epsilon variants; light-green), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants; light-blue), and the prevalences of GIII (from all Omicron-derived variants; light-red) were obtained for neighboring countries of Bolivia using publicly accessible genomic data when available.